PROCTER & GAMBLE HEALTH | MANGALAM DRUGS | PROCTER & GAMBLE HEALTH/ MANGALAM DRUGS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | -9.4 | - | View Chart |
P/BV | x | 10.6 | 1.0 | 1,006.8% | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH MANGALAM DRUGS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
MANGALAM DRUGS Mar-23 |
PROCTER & GAMBLE HEALTH/ MANGALAM DRUGS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 173 | 3,107.8% | |
Low | Rs | 3,883 | 95 | 4,087.4% | |
Sales per share (Unadj.) | Rs | 740.7 | 235.2 | 315.0% | |
Earnings per share (Unadj.) | Rs | 138.2 | 0.8 | 17,230.4% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 7.7 | 2,003.6% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 96.0 | 466.3% | |
Shares outstanding (eoy) | m | 16.60 | 15.83 | 104.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 0.6 | 1,097.1% | |
Avg P/E ratio | x | 33.5 | 166.8 | 20.1% | |
P/CF ratio (eoy) | x | 29.8 | 17.3 | 172.5% | |
Price / Book Value ratio | x | 10.3 | 1.4 | 741.1% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 2,118 | 3,623.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 346 | 595.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 3,723 | 330.3% | |
Other income | Rs m | 184 | 4 | 4,217.9% | |
Total revenues | Rs m | 12,480 | 3,727 | 334.9% | |
Gross profit | Rs m | 3,247 | 255 | 1,272.4% | |
Depreciation | Rs m | 281 | 110 | 255.7% | |
Interest | Rs m | 8 | 128 | 6.0% | |
Profit before tax | Rs m | 3,142 | 22 | 14,191.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 9 | 8,975.6% | |
Profit after tax | Rs m | 2,295 | 13 | 18,068.5% | |
Gross profit margin | % | 26.4 | 6.9 | 385.2% | |
Effective tax rate | % | 27.0 | 42.6 | 63.3% | |
Net profit margin | % | 18.7 | 0.3 | 5,470.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 2,066 | 567.0% | |
Current liabilities | Rs m | 6,791 | 1,654 | 410.7% | |
Net working cap to sales | % | 40.0 | 11.1 | 361.4% | |
Current ratio | x | 1.7 | 1.2 | 138.1% | |
Inventory Days | Days | 263 | 1 | 22,461.9% | |
Debtors Days | Days | 343 | 456 | 75.3% | |
Net fixed assets | Rs m | 10,617 | 1,530 | 693.7% | |
Share capital | Rs m | 166 | 158 | 104.9% | |
"Free" reserves | Rs m | 7,265 | 1,361 | 533.7% | |
Net worth | Rs m | 7,431 | 1,520 | 489.0% | |
Long term debt | Rs m | 0 | 188 | 0.0% | |
Total assets | Rs m | 22,330 | 3,596 | 620.9% | |
Interest coverage | x | 409.1 | 1.2 | 34,853.5% | |
Debt to equity ratio | x | 0 | 0.1 | 0.0% | |
Sales to assets ratio | x | 0.6 | 1.0 | 53.2% | |
Return on assets | % | 10.3 | 3.9 | 264.5% | |
Return on equity | % | 30.9 | 0.8 | 3,695.1% | |
Return on capital | % | 42.4 | 8.8 | 483.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 25.7 | 50.7% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | 958 | 167.5% | |
Fx inflow | Rs m | 1,465 | 1,078 | 135.9% | |
Fx outflow | Rs m | 1,605 | 978 | 164.2% | |
Net fx | Rs m | -140 | 100 | -139.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 395 | 597.1% | |
From Investments | Rs m | -215 | -222 | 97.0% | |
From Financial Activity | Rs m | -985 | -166 | 592.6% | |
Net Cashflow | Rs m | 1,160 | 7 | 15,807.9% |
Indian Promoters | % | 0.0 | 50.3 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 0.3 | 7,680.8% | |
FIIs | % | 6.2 | 0.3 | 2,400.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 49.7 | 97.0% | |
Shareholders | 56,778 | 19,173 | 296.1% | ||
Pledged promoter(s) holding | % | 0.0 | 17.6 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | MANGALAM DRUGS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | -0.85% | 0.45% |
1-Month | -1.15% | 3.70% | 2.55% |
1-Year | 0.73% | -12.29% | 56.14% |
3-Year CAGR | -8.76% | -12.70% | 15.22% |
5-Year CAGR | 4.97% | 13.03% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the MANGALAM DRUGS share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of MANGALAM DRUGS the stake stands at 50.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of MANGALAM DRUGS.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
MANGALAM DRUGS paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of MANGALAM DRUGS.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.